RESEARCH COLLABORATION AND OPTION TO LICENSE AGREEMENT by and between SYNTHETIC GENOMICS, INC. and MERCK SHARP & DOHME CORP.License Agreement • August 14th, 2019 • Armata Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
This Research Collaboration and Option to License Agreement (this “Agreement”) is effective as of May 22, 2017 (the “Effective Date”) and is entered into by and between SYNTHETIC GENOMICS, INC., a corporation organized and existing under the laws of Delaware (“Company”), and MERCK SHARP & DOHME CORP., a corporation organized and existing under the laws of New Jersey (“Merck”).
ASSET PURCHASE AGREEMENTAsset Purchase Agreement • August 14th, 2019 • Armata Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Washington
THIS ASSET PURCHASE AGREEMENT (this “Agreement”), dated as of February 14, 2018, is made by and between C3J THERAPEUTICS, INC., a Washington corporation (“Purchaser”), and SYNTHETIC GENOMICS, INC., a Delaware corporation, and SYNTHETIC GENOMICS VACCINES, INC., a Delaware corporation (collectively, “Seller”). Purchaser and Seller may be referred to herein collectively as the “Parties” and individually as a “Party.”
